People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2019 |
Daniel Chevallard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Chevallard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Soon-Shiong | 1 | 16 |
| Ivor Royston | 1 | 7 |
| Paul Goddard | 1 | 4 |
| James Woody | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| Ronald Berenson | 1 | 3 |
| James N. Woody | 1 | 3 |
| Frederick Dotzler | 1 | 3 |
| Armen Shanafelt | 1 | 3 |
| Barry Simon | 1 | 3 |
| Wayne Roe | 1 | 2 |
| MICHAEL HUANG | 1 | 2 |
| Gur Roshwalb | 1 | 2 |
| James P. Woody | 1 | 1 |
| Paul P. Goddard | 1 | 1 |
| Tamara P. Seymour | 1 | 1 |
| Ivor P. Royston | 1 | 1 |
| Richard Ghalie | 1 | 1 |
| Samuel Murphy | 1 | 1 |
| David Slack | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.